These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes. Weintrob N; Shalitin S; Phillip M Isr Med Assoc J; 2004 May; 6(5):271-5. PubMed ID: 15151365 [TBL] [Abstract][Full Text] [Related]
35. [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1]. Jarosz-Chobot P Wiad Lek; 2004; 57(5-6):263-6. PubMed ID: 15518073 [TBL] [Abstract][Full Text] [Related]
36. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098 [TBL] [Abstract][Full Text] [Related]
38. Hyperkalaemia, ketoacidosis and subcutaneous or intravenous insulin infusions. MacRury SM; Small M; MacCuish AC Diabetes Res; 1987 Jul; 5(3):153-5. PubMed ID: 3117474 [TBL] [Abstract][Full Text] [Related]
39. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Holstein A; Stege H; Kovacs P Expert Opin Drug Saf; 2010 Mar; 9(2):225-31. PubMed ID: 20001763 [TBL] [Abstract][Full Text] [Related]
40. Reversal of insulin lipoatrophy by monocomponent insulin. Aw TC; Ee BK; Cheah JS Singapore Med J; 1978 Dec; 19(4):227-30. PubMed ID: 751208 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]